Mitoferrin-1 and -2 (Mfrn1/2) boost mitochondrial iron uptake, which may be advantageous under normal conditions but can have adverse effects on iron dyshomeostasis, such as increased expression of Mfrn1/2 in PD models [160]. Here, SLC25A37 is linked to Parkinson disease.